SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a private exchange of $1.4 billion in convertible notes for common stock, a move intended to clean up the balance sheet by reducing long-term debt. While the community is sharply divided, with some investors praising the move as a strategic step toward future acquisitions and others condemning the potential dilution, many are actively speculating whether this financial restructuring serves as a catalyst for a larger strategic pivot.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing heightened volatility and intense short interest as investors brace for the company's first earnings report and a massive insider share lock-up expiration. The community remains deeply divided between long-term bulls betting on disruptive space and AI infrastructure and bears anticipating significant downward pressure from a sudden, substantial increase in the tradable float.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong investor interest as it continues to expand its Briumvi multiple sclerosis franchise and advances its pipeline into new indications like schizophrenia. The community is actively discussing the stock's significant long-term growth potential and commercial momentum, while frequently speculating about potential buyout scenarios as larger pharmaceutical companies look to address patent cliffs.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to strong earnings results that highlight significant revenue growth, record store expansion, and continued momentum in monthly transacting customers despite broader market uncertainty. Community sentiment remains polarized between long-term bulls encouraged by the company's operational execution and profitability and skeptical traders debating the long-term viability of its OTC listing status.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as market participants debate whether the recent sell-off in memory stocks is a structural reversal driven by geopolitical concerns and slowing demand, or a temporary liquidity-driven shakeout. Community members are divided, with many citing robust hyperscaler capex and long-term memory supply constraints as reasons to hold, while others are bracing for further volatility due to broader sector rotation and fears of a cooling AI hardware cycle.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is capturing significant market attention following a high-profile oncology collaboration with Janux Therapeutics and positive Phase 3 data for mezigdomide, strengthening its pipeline as the company works to offset revenue pressure from legacy drug patent expirations. Community discussion is heavily focused on whether these strategic moves, combined with robust dividend stability, are sufficient to drive a long-term growth turnaround in a competitive pharmaceutical landscape.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca's stock is experiencing heightened market activity following a high-profile report of preliminary merger talks with Bristol Myers Squibb aimed at creating a $400 billion pharmaceutical powerhouse focused on oncology. Community discussions are heavily centered on the potential for massive operational synergies, aggressive cost-cutting measures, and the significant antitrust hurdles that such a historic industry consolidation would face.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Investors are closely monitoring geopolitical developments in the Middle East and their potential impact on market stability, while the community actively debates whether current equity valuations are sustainable or signaling a broader economic downturn. Sentiment remains polarized as market participants weigh potential inflationary pressures against ongoing corporate performance and technical trading signals.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is experiencing significant volatility following a mixed Q2 earnings report where profitability and margins impressed investors despite a revenue forecast that fell slightly short of analyst expectations. The community remains divided, with some highlighting the company's strong domestic manufacturing moat and robust order backlog, while others express concerns over valuation, impending tariff-related legal headlines, and the long-term impact of potential subsidy phase-outs.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors eagerly anticipate topline results from the Phase 3 IZAR-1 trial for sonelokimab, a key catalyst expected to demonstrate best-in-class efficacy in psoriatic arthritis. The community is actively debating the precise timing of this data release following management's recent guidance, while simultaneously weighing the potential for a significant M&A event given the stock's strong institutional backing and multi-indication pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
